Kronos Bio, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 14 rows in 2022. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2022-07-25: Reporting owner Al-Wakeel Yasir B.; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-06-22: Reporting owner Yang Taiyin; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-06-22: Reporting owner De Backer Marianne; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2022-06-22: Reporting owner Blunt Roshawn A.; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2022-07-25 | Al-Wakeel Yasir B. Officer (Chief Financial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $5.02 exercise price | 2022-07-27 | |
| 2022-06-22 | Yang Taiyin Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,000 17,000 owned after | $3.53 exercise price | 2022-06-29 | |
| 2022-06-22 | De Backer Marianne Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,000 17,000 owned after | $3.53 exercise price | 2022-06-29 | |
| 2022-06-22 | Blunt Roshawn A. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $3.53 exercise price | 2022-06-29 | |
| 2022-06-22 | Stampacchia Otello Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $3.53 exercise price | 2022-06-29 | |
| 2022-06-22 | Ridloff Elena Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $3.53 exercise price | 2022-06-29 | |
| 2022-06-22 | Kazam Joshua A Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $3.53 exercise price | 2022-06-29 | |
| 2022-06-22 | TANEN DAVID M Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $3.53 exercise price | 2022-06-29 | |
| 2022-06-22 | Belldegrun Arie Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +34,000 34,000 owned after | $3.53 exercise price | 2022-06-29 | |
| 2022-02-16 | BISCHOFBERGER NORBERT W Director, Officer (President & CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +400,000 400,000 owned after | $7.30 exercise price | 2022-02-17 | |
| 2022-02-15 | Kosacz Barbara Officer (COO & General Counsel) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $7.08 exercise price | 2022-02-17 | |
| 2022-02-15 | DiMartino Jorge Officer (Chief Medical Officer & VP) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +90,000 90,000 owned after | $7.08 exercise price | 2022-02-17 | |
| 2022-02-15 | Dinsmore Christopher Officer (Chief Scientific Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +65,000 65,000 owned after | $7.08 exercise price | 2022-02-17 | |
| 2022-02-15 | Al-Wakeel Yasir B. Officer (Chief Financial Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +80,000 80,000 owned after | $7.08 exercise price | 2022-02-17 |